Prevalence of Hepatitis D Virus Infection Among Hepatitis B Virus Infected Patients in Qom Province, Center of Iran

Abstract

Context: Hepatitis C virus (HCV) infection is a significant cause of chronic liver disease in patients with human immunodeficiency virus (HIV) infection. Introduction of HCV direct-acting antiviral agents (DAAs) revolutionized the treatment of hepatitis C in patients with HIV/HCV co-infection. In this study, we systematically reviewed the treatment of chronic HCV infection in patients with HIV/HCV co-infection. Evidence Acquisition: In this systematic review, electronic databases including PubMed, Scopus, ScienceDirect, and Web of Science were comprehensively searched using appropriate strategies containing all related keywords of "HCV", "HIV" and "DAA". Studies assessed the effectiveness of interferon-free HCV antiviral therapies in patients with HIV/HCV co-infection were evaluated for inclusion in the systematic review. Results: After the screening of 728 records, we included 33 articles in our study, and seven different HCV antiviral regimens were evaluated. Ten studies for sofosbuvir plus simeprevir (SVR ranged from 72.2% to 100%), eight studies for sofosbuvir plus ribavirin (SVR ranged from 51.6% to 91.6%), 12 studies for sofosbuvir/ledipasvir (SVR ranged from 88.8% to 100%), eight studies for sofosbuvir plus daclatasvir (SVR ranged between 84.6% and 100%), two studies for grazoprevir/elbasvir (SVR ranged from 86.6% to 96.5%), six studies for ombitasvir/paritaprevir/ritonavir plus dasabuvir (SVR ranged from 90.6% to 100%), and just one study for sofosbuvir/velpatasvir with 95.2% SVR rate. Conclusions: This study found that treatment of HCV infection with DAAs can result in high SVR rate in patients with HIV/HCV co-infection.

Comprehensive analysis of mutations in the hepatitis delta virus genome based on full-length sequencing in a nationwide cohort study and evolutionary pattern during disease progression

“…Due to global HBV vaccination programmes since the 1990s, HDV infection has been relatively well controlled in Europe, especially Western Europe [1]. In contrast, several countries in the Middle East are considered endemic regions for HDV infections [9][10][11][12][13]. Despite partial or full genome analyses of HDV reported from distinct geographical areas [14,15], there are limited data available on the molecular evolution of HDV from this region, particularly Iran [9,[16][17][18][19].…”

Disseminated Staphylococcus aureus infection after scarification wet cupping therapy: a case report and literature review

“…Also, not all the AEs related to cupping therapy are recorded or published, since there are no rigorous AE registration systems for cupping [ 11 ]. Furthermore, we have not found any case reports of hepatitis secondary to cupping therapy, even though several studies have reported that acupuncture and cupping are risk factors for HCV infection in Egypt [ 27 – 29 ] and HDV infection in Iran [ 30 ], presumably through transmission from infected needles.…”

Common complications of hemodialysis: A clinical review

“…[50] Globally, HDV appears in about 5% of HBV-infected individuals. [51] Patients on HD patients are at a higher risk of HDV infection. [52] HDV infection can present as a co-infection or super-infection.…”